Abstract
Viscoelastic testing includes thromboelastography (TEG®) and thromboelastometry (ROTEM®) and is widely used in bleeding patients to detect hypocoagulability and guide transfusion therapy. However, the ability of standard viscoelastic tests to assess fibrinolytic capacity is limited. We here describe a modified ROTEM® protocol with addition of tissue plasminogen activator that can be used to identify hypofibrinolysis or hyperfibrinolysis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hartert H (1948) Blood clotting studies with thrombus stressography; a new investigation procedure. Klin Wochenschr 26:577–583
Benes J, Zatloukal J, Kletecka J (2015) Viscoelastic methods of blood clotting assessment – a multidisciplinary review. Front Med (Lausanne) 2:62
Weber CF, Gorlinger K, Meininger D et al (2012) Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 117:531–547
Fayed N, Mourad W, Yassen K, Görlinger K (2015) Preoperative thromboelastometry as a predictor of transfusion requirements during adult living donor liver transplantation. Transfus Med Hemother 42:99–108
Gonzalez E, Moore EE, Moore HB et al (2016) Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg 263:1051–1059
Wada H, Matsumoto T, Ohishi K et al (2020) Update on the clot waveform analysis. Clin Appl Thromb Hemost 26:1076029620912027
Wikkelso A, Wetterslev J, Moller AM, Afshari A (2016) Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016:CD007871
Nath SS, Pandey CK, Kumar S (2022) Clinical application of viscoelastic point-of-care tests of coagulation-shifting paradigms. Ann Card Anaesth 25:1–10
Lisman T (2020) Interpreting hemostatic profiles assessed with viscoelastic tests in patients with cirrhosis. J Clin Gastroenterol 54:389–391
Leebeek FW, Rijken DC (2015) The fibrinolytic status in liver diseases. Semin Thromb Hemost 41:474–480
Chapman MP, Moore EE, Moore HB et al (2015) The “death diamond”: rapid thromboelastography identifies lethal hyperfibrinolysis. J Trauma Acute Care Surg 79:925–929
Larsen JB, Aggerbeck MA, Larsen KM et al (2021) Fibrin network formation and lysis in septic shock patients. Int J Mol Sci 22:9540
Hvas CL, Larsen JB, Adelborg K et al (2022) Dynamic hemostasis and fibrinolysis assays in intensive care COVID-19 patients and association with thrombosis and bleeding – a systematic review and a cohort study. Semin Thromb Hemost 48:31–54
Blasi A, Patel VC, Adelmeijer J et al (2019) Mixed fibrinolytic phenotypes in decompensated cirrhosis and acute-on-chronic liver failure with hypofibrinolysis in those with complications and poor survival. Hepatology 71:1381–1390
Memtsas VP, Arachchillage DRJ, Gorog DA (2021) Role, laboratory assessment and clinical relevance of fibrin, factor XIII and endogenous fibrinolysis in arterial and venous thrombosis. Int J Mol Sci 22:1472
Undas A (2021) Fibrinolysis in venous thromboembolism. Semin Thromb Hemost 47:480–489
Nikfardjam M, Graf S, Beckmann R et al (1999) Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease. Thromb Haemost 82(Suppl 1):80–84
Hvas AM, Sørensen HT, Norengaard L et al (2007) Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia a. J Thromb Haemost 5:2408–2414
Mittermayr M, Streif W, Haas T et al (2008) Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo. Br J Anaesth 100:307–314
Shenkman B, Livnat T, Budnik I et al (2012) Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator. Blood Coagul Fibrinolysis 23:729–733
Kuiper GJ, Kleinegris MC, van Oerle R et al (2016) Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity. Thromb J 14:1
Thalén S, Forsling I, Eintrei J et al (2013) Pneumatic tube transport affects platelet function measured by multiplate electrode aggregometry. Thromb Res 132:77–80
Shaw GJ, Sperling M, Meunier JM (2009) Long-term stability of recombinant tissue plasminogen activator at −80 C. BMC Res Notes 2:117
Kallner A, Theodorsson E (2020) Repeatability imprecision from analysis of duplicates of patient samples and control materials. Scand J Clin Lab Invest 80:210–214
Acknowledgments
The authors would like to thank Vivi Bo Mogensen and Tine Kusk Jørgensen for their invaluable assistance in the laboratory.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Larsen, J.B., Hvas, C.L., Hvas, AM. (2023). Modified Rotational Thromboelastometry Protocol Using Tissue Plasminogen Activator for Detection of Hypofibrinolysis and Hyperfibrinolysis. In: Favaloro, E.J., Gosselin, R.C. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 2663. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3175-1_51
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3175-1_51
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3174-4
Online ISBN: 978-1-0716-3175-1
eBook Packages: Springer Protocols